echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > 1.5 billion blood lipid drugs Nanjing Changgao Pharmaceuticals is about to enter the bureau

    1.5 billion blood lipid drugs Nanjing Changgao Pharmaceuticals is about to enter the bureau

    • Last Update: 2020-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pharmaceutical Network June 18th, June 11, Nanjing Changgao Pharmaceutical's pivastatin calcium tablets (acceptance number CYHS1800199) imitation 4 categories of listing applications into the administrative approval stage, is expected to be approved for listing in the near futureAccording to Minet.com, sales of pappatartininatin at the end of China's public medical facilities in 2019 were 1.552 billion yuan, up 47.50 percent year-on-yearPivastatin is used to treat hypercholesterolemia, familial hypercholesterolemia, is a third-generation statin, has a lower effective dose than other listed statins, and has a drug metabolism of P450 (CYP) metabolism (CYP2C9 has very little metabolism) that reduces possible drug interactionsAccording to Minet.com, sales of pedestalatin at the end of China's urban publichospitals
    , county-level public hospitals, urban community centers and township hospitals (referred to as Public Medical Institutions in China) in 2019 were 1.552 billion yuan, up 47.50 percent year-on-yearAmong them, China Resources Shuanghe occupies 43.56 percent of the market share, Wanbang Pharmaceuticals accounted for 20.75 percent, the original research manufacturer Ofjapan Xinghe market share of only 12.73 percentChina's public medical institutions terminal pivastatin sales (units: 10,000 yuan)the current domestic market pivastatin products have pivastatin calcium tablets, pivastatin calcium dispersed tabletsPivastatin calcium dispersion tablets only Beijing New Pharmaceuticals has a production approvalPivastatin calcium tablet scantilys manufacturers have Japan Xinghe, Ilitai, Qidu Pharmaceuticals, China Resources Shuanghe, Wanbang Pharmaceuticals and other 5With the first collection of atovastatin calcium tablets, rishuastatin calcium tablets two statin prices of the "diving", pivastatin has become a new focus of the marketMinnet consistency evaluation database shows that at present, only the pevastatin evaluation enterprises only Xinlitai, WanbangpharmaceuticaltwoenterprisesNanjing Changgao Pharmaceutical Pivastatin calcium tablets according to imitation 4 categories of production, if successfully approved will become the third species of the evaluation enterprise   Pivastatin reviews of enterprise Source: CDE Website, Mitan.com
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.